



PledPharma

PRESS RELEASE

30 March 2020 10:30:00 CEST

PledPharma's 2019 annual report published

PledPharma AB today announced that the Annual Report for 2019 now is available at the company's website, www.pledpharma.se.

A printed version can be ordered through info@pledpharma.se or +468 -679 72 10.

Contacts

Nicklas Westerholm, CEO, phone: +46 73 354 20 62

nicklas.westerholm@pledpharma.se

Yilmaz Mahshid, CFO, phone: +46 72 231 68 00

yilmaz.mahshid@pledpharma.se

About Us

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company's most advanced project **PledOx**[®] is being developed to reduce nerve damage associated with chemotherapy. A phase III program is ongoing. The drug candidate **Aladote**[®] is being developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning. A proof of principle study has been successfully completed and the design of the next study is being finalised. Aladote[®] has been granted Orphan Drug Designation in the US. PledPharma (STO: PLED) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see <http://www.pledpharma.com/>

Attachments

[PledPharma's 2019 annual report published](#)